{{medical}}
{{drugbox |
|width = 350
|image=Ranitidine Structural Formulae.png
|image2=Ranitidine-A-3D-balls.png

<!--Clinical data-->
| pronounce = {{IPAc-en|r|ə|ˈ|n|ɪ|t|ᵻ|d|iː|n}}
| tradename = Zantac, others
| Drugs.com = {{drugs.com|monograph|ranitidine-hydrochloride}}
| MedlinePlus = a601106
| licence_US = Ranitidine
| pregnancy_AU = B1
| pregnancy_US = B
| legal_AU = S2
| legal_US = OTC
| legal_US_comment = / Rx-only
| legal_UK = GSL
| routes_of_administration = 口服、[[静脉滴注|静脉滴注]]

|IUPAC_name = <nowiki>N'-甲基-N-[2-[[[5-[（二甲氨基）甲基]-2-呋喃基]-甲基]硫代]乙基]-2-硝基-1,1-乙烯二胺</nowiki><!-- IUPAC 不该中文吧？ -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 66357-35-5
| ATC_prefix = A02
| ATC_suffix = BA02
| ATC_supplemental = <br />{{ATC|A02BA|07}} (ranitidine bismuth citrate)
| IUPHAR_ligand = 1234
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00863
| PubChem = 3001055
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4863
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 884KT10YB7
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00422
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 8776
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1790041
| synonyms = Dimethyl [(5-<nowiki/>{[(2-<nowiki/>{[1-(methylamino)-<br />2-nitroethenyl]amino}ethyl)sulfanyl]<br />methyl}furan-2-yl)methyl]amine

| C=13 | H=22 | N=4 | O=3 | S=1
| molecular_weight = 314.4 g/mol
| smiles = CNC(=C[N+](=O)[O-])NCCSCc1ccc(o1)CN(C)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VMXUWOKSQNHOCA-UHFFFAOYSA-N

<!--Pharmacokinetic data-->
|bioavailability = 39 to 88%
|metabolism = [[肝脏|肝脏]]
|elimination_half-life = 2–3 小时
|excretion = 30–70% [[肾脏|肾脏]]
|pregnancy_category = 孕妇及哺乳期妇女禁用
|legal_status = [[非处方药|非处方药]]
|routes_of_administration = [[口服|口服]]
}}

'''雷尼替丁'''（{{lang|en|Ranitidine}}、中華藥典名：雷尼替定<ref>中華藥典第六版 頁1304</ref>），常用商品名'''Zantac'''，是一种抑制[[胃酸|胃酸]]<ref name=AHFS2015/>产生的[[组胺|组胺]]类[[H2受体阻抗剂|H<sub>2</sub>受体阻抗剂]]。它常用于治疗[[消化性溃疡|消化性溃疡]]（如[[胃溃疡|胃溃疡]]和[[十二指肠溃疡|十二指肠溃疡]]）以及[[胃食管反流病|胃食管反流病]]。此外，該藥或許還能改善[[荨麻疹|荨麻疹]]的症狀<ref>{{cite journal|last1=Fedorowicz|first1=Z|last2=van Zuuren|first2=EJ|last3=Hu|first3=N|title=Histamine H2-receptor antagonists for urticaria.|journal=The Cochrane database of systematic reviews|date=14 March 2012|volume=3|pages=CD008596|pmid=22419335}}</ref>。本品可經口服、[[肌肉注射|肌肉注射]]，或[[靜脈注射|靜脈注射]]給藥<ref name=AHFS2015/> 。

<!-- Side effects and mechanism -->
注射劑常見副作用包含[[頭痛|頭痛]]以及灼熱感<!-- <ref name=AHFS2015/> -->，嚴重副作用則包含肝臟疾病、[[心跳过缓|心跳过缓]]、[[肺炎|肺炎]]，且可能使[[胃癌|胃癌]]更不易發現<ref name=AHFS2015/>。本品也可能提升[[偽膜性結腸炎|偽膜性結腸炎]]的風險<ref>{{cite journal|last1=Tleyjeh|first1=IM|last2=Abdulhak|first2=AB|last3=Riaz|first3=M|last4=Garbati|first4=MA|last5=Al-Tannir|first5=M|last6=Alasmari|first6=FA|last7=Alghamdi|first7=M|last8=Khan|first8=AR|last9=Erwin|first9=PJ|last10=Sutton|first10=AJ|last11=Baddour|first11=LM|title=The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis.|journal=PloS one|date=2013|volume=8|issue=3|pages=e56498|pmid=23469173}}</ref>。[[妊娠|妊娠]]期間給藥目前顯示安全<!-- <ref name=AHFS2015/> -->。本品屬於[[組織胺|組織胺]][[H2受体阻抗剂|H<sub>2</sub>受体阻抗剂]]，可降低胃酸的分泌<ref name=AHFS2015>{{cite web|title=Ranitidine|url=http://www.drugs.com/monograph/ranitidine-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=Dec 1, 2015|archive-date=2017-05-01|archive-url=https://web.archive.org/web/20170501195401/https://www.drugs.com/monograph/ranitidine-hydrochloride.html|dead-url=no}}</ref>。

<!-- History, society and culture -->
雷尼替丁最早於1976年由葛蘭素製藥（Glaxo Pharmaceuticals）發現，現屬於[[葛蘭素史克|葛蘭素史克]]的一部分<ref>{{cite book|last1=Fischer|first1=Janos|title=Analogue-based Drug Discovery II|date=2010|publisher=John Wiley & Sons|page=4|isbn=9783527632121|url=https://books.google.ca/books?id=h2Kd8ci4Ln8C&pg=PA4|access-date=2017-03-15|archive-date=2016-03-05|archive-url=https://web.archive.org/web/20160305025141/https://books.google.ca/books?id=h2Kd8ci4Ln8C&pg=PA4|dead-url=no}}</ref><ref>{{cite book|last1=Hara|first1=Takuji|title=Innovation in the pharmaceutical industry the process of drug discovery and development|date=2003|publisher=Edward Elgar|location=Cheltenham, U.K.|isbn=9781843765660|page=94|url=https://books.google.ca/books?id=aYP-AQAAQBAJ&pg=PA94|access-date=2017-03-15|archive-date=2016-03-05|archive-url=https://web.archive.org/web/20160305043815/https://books.google.ca/books?id=aYP-AQAAQBAJ&pg=PA94|dead-url=no}}</ref>。本品列名於[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]之中，為基礎公衛體系必備藥物之一<ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013|archive-date=2014-04-23|archive-url=https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|dead-url=no}}</ref>雷尼替丁为一[[學名藥|學名藥]]。<ref name=AHFS2015/>。本品批發價每顆約位於0.01至0.05美金之間<ref>{{cite web|title=Ranitidine|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RAN150T&s_year=2014&year=2014&str=150%20mg&desc=Ranitidine&pack=new&frm=TAB-CAP&rte=PO&class_code2=17%2E1%2E&supplement=&class_name=%2817%2E1%2E%29Antiulcer%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=1 December 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20170510161832/http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RAN150T&s_year=2014&year=2014&str=150%20mg&desc=Ranitidine&pack=new&frm=TAB-CAP&rte=PO&class_code2=17%2E1%2E&supplement=&class_name=%2817%2E1%2E%29Antiulcer%20medicines%3Cbr%3E|archivedate=2017年5月10日}}</ref>。美國境內一劑約需0.05美金<ref name=AHFS2015/>。

== 临床应用 ==
在许多[[国家|国家]]，特定剂量的雷尼替丁制剂是非处方药品。

[[美国|美国]]以外，雷尼替丁常与[[铋|铋]]（作为一个温和的抗生素）合成的柠檬酸盐（雷尼替丁枸橼酸铋）用于治疗[[幽门螺杆菌|幽门螺杆菌]]感染。这一组合通常是与[[克拉霉素|克拉霉素]]（一种[[抗生素|抗生素]]）一起使用。

==警告和注意事項==
<!--===不純物質===-->
[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）得知，有些雷尼替丁藥物（包括商品名為Zantac的藥物）中含有低劑量的 [[N-亚硝基二甲胺|N-亚硝基二甲胺]]（NDMA）。NDMA分類為可能的人類致癌物<ref>{{cite web|title=Statement alerting patients and health care professionals of NDMA found in samples of ranitidine|url=https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine|date=2019-09-13|access-date=15 September 2019-09-15|publisher=Food and Drug Administration (FDA)|archive-date=2019-09-26|archive-url=https://web.archive.org/web/20190926210751/https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine|dead-url=no}}{{PD-notice}}</ref>。加拿大的衛生單位也發表聲明，指出他們雷尼替丁中檢測到在NDMA<ref>{{cite web | title=Recalls and safety alerts | website=Health Canada assessing NDMA in ranitidine | date=13 September 2019 | url=https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php | access-date=2019-09-19 | archive-date=2019-09-19 | archive-url=https://web.archive.org/web/20190919021701/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/70989a-eng.php | dead-url=no }}</ref>，並且要求製造商停止在加拿大販售雷尼替丁藥物，到產品中的NDMA濃度在安全範圍內才能再販售<ref>{{cite web | title=Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; some products being recalled - Recalls and safety alerts | website=Health Canada | date=2019-09-17 | url=https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php | access-date=2019-09-19 | archive-date=2019-09-19 | archive-url=https://web.archive.org/web/20190919021621/https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php | dead-url=no }}</ref>。由於歐盟委員會的要求，歐盟藥物管理局已在全歐盟審查含有雷尼替丁的藥物<ref>{{cite press release | title=EMA to provide guidance on avoiding nitrosamines in human medicines | website=European Medicines Agency (EMA) | date=2019-09-13 | url=https://www.ema.europa.eu/en/news/ema-provide-guidance-avoiding-nitrosamines-human-medicines | access-date=2019-09-19 | archive-date=2019-12-31 | archive-url=https://web.archive.org/web/20191231050132/https://www.ema.europa.eu/en/news/ema-provide-guidance-avoiding-nitrosamines-human-medicines | dead-url=no }}</ref><ref>{{cite press release | title=EMA to review ranitidine medicines following detection of NDMA | website=European Medicines Agency (EMA) | date=2019-09-13 | url=https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma | access-date=2019-09-19 | archive-date=2020-02-13 | archive-url=https://web.archive.org/web/20200213014926/https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma | dead-url=no }}</ref>。中華民國衛生福利部食品藥物署已要求含有雷尼替丁的藥物，先進行預防性下架<ref>{{Cite web |title=食藥署要求全面預防性下架含ranitidine成分藥品，經檢驗確認合格後，始得重新上架。 |url=https://www.fda.gov.tw/tc/newsContent.aspx?cid=4&id=t549071 |accessdate=2019-09-21 |author=中華民國衛生福利部食品藥物管理署 |date=2019-09-20 |language=zh}}</ref>。

山德士（Sandoz）公司已針對所有含有雷尼替丁的藥物提出「預防性下架」（precautionary distribution stop）<ref>{{cite news | last=Bomey | first=Nathan | title=Ranitidine warnings: Generic Zantac distribution halted on cancer fear | website=USA Today | date=September 19, 2019 | url=https://www.usatoday.com/story/money/2019/09/19/generic-zantac-ranitidine-sandoz-distribution-stop-novartis/2372161001/ | access-date=2019-09-20 | archive-date=2019-09-20 | archive-url=https://web.archive.org/web/20190920191731/https://www.usatoday.com/story/money/2019/09/19/generic-zantac-ranitidine-sandoz-distribution-stop-novartis/2372161001/ | dead-url=no }}</ref><ref>{{cite web | last=Palmer | first=Eric | title=Novartis doesn't wait for FDA investigation and halts distribution of its generic Zantac | website=FiercePharma | date=2019-09-19 | url=https://www.fiercepharma.com/manufacturing/novartis-doesn-t-wait-for-fda-investigation-and-halts-distribution-its-generic-zantac | access-date=2019-09-20 | quote=Novartis on Wednesday said it was stopping worldwide distribution of its generic versions of the antacid while regulators investigate the fact that the impurity N-nitrosodimethylamine (NDMA) has been detected these ranitidine-based drugs. | archive-date=2019-09-20 | archive-url=https://web.archive.org/web/20190920222801/https://www.fiercepharma.com/manufacturing/novartis-doesn-t-wait-for-fda-investigation-and-halts-distribution-its-generic-zantac | dead-url=no }}</ref>。
== 历史 ==
史克公司（Smith, Kline & French）发明了第一种组胺H<sub>2</sub>受体拮抗剂[[西咪替丁|西咪替丁]]。[[葛兰素公司|葛兰素公司]]（Glaxo）为了与史克公司竞争，发明了雷尼替丁。雷尼替丁是[[合理化药物设计|合理化药物设计]]的产物，是根据当时相当完善的组胺H<sub>2</sub>受体模型和[[定量构效关系|定量构效关系]]（QSAR）设计的。

葛兰素公司进一步完善了这个模型。他们用一个[[呋喃|呋喃]]环取代了西咪替丁上的[[咪唑|咪唑]]环，这使得雷尼替丁大为发展，有更好的耐受性，更少的[[不良反應_(醫學)|不良反应]]，更长的作用时间，以及10倍于西咪替丁的活性。因为雷尼替丁对于細胞色素P450的亲和力只有西咪替丁的10%，所以其副作用较少，但其他的H<sub>2</sub>受体拮抗剂如[[法莫替丁|法莫替丁]]和[[尼扎替丁|尼扎替丁]]则与细胞色素P450没有明显的活性。<ref>Goodman and Gilman's page 972 11th addition</ref>

雷尼替丁出现于1981年，并于1988年称为世界上销售最多的处方药。但是当更有效的[[质子泵抑制剂|质子泵抑制剂]]出现后，他已经逐渐被[[奥美拉唑|奥美拉唑]]等药物所取代。

== 参考文献 ==
{{reflist|2}}

== 外部链接 ==
*[http://www.gsk.com.au/products_consumer-healthcare-products_product-listing.aspx?view=52] {{Wayback|url=http://www.gsk.com.au/products_consumer-healthcare-products_product-listing.aspx?view=52 |date=20080721152430 }} - Consumer information on Zantac from the manufacturer.

{{消化道溃疡和胃食管反流病治疗药物}}
{{Histaminergics}}
{{GlaxoSmithKline}}

[[Category:药物|Category:药物]]
[[Category:H2受体拮抗剂|Category:H2受体拮抗剂]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:肝毒素|Category:肝毒素]]
[[Category:1970年代发现的物质|Category:1970年代发现的物质]]